Will05UW
Oct 23, 5:09 PM
$CRVO Practical Sequencing Ph3 Scenario: Secure gvrnmt (and philanthropic) commitments first or in parallel — these provide non-dilutive capital and external validation that makes the asset more attractive to a strategic partner. Negotiate the strategic prtnrshp with explicit contingent language: prtnr funds the residual bdgt once non-dilutive sources are used (or upon positive interim). Optionally add adaptive/interim features to the trial design so that early data can trigger the next funding tranche or allow early stopping, further protecting all parties. Bottom line: A combo of
$15–30M+ in milestone-driven gvrnmt funding,
$5–15Min philanthropic/impact capital, and a strategic ptnr covering the large remaining majority (with staged commitment) is a viable path. The partner’s willingness to backstop the remainder after non-dilutive funds are exhausted is both feasible and a standard risk-sharing tool that improves the odds of getting the Ph3 fully funded w/out excessive dilution.
0 replies
